Los Angeles Capital Management
RCKT icon

Los Angeles Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Los Angeles Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-187,401
Closed -$693K – 2566
2025
Q4 		$693K Sell
187,401
-77,030
-29% -$264K ﹤0.01% 772
2025
Q3 		$862K Buy
264,431
+189,514
+253% +$597K ﹤0.01% 745
2025
Q2 		$184K Buy
+74,917
New +$380K ﹤0.01% 1208
2024
Q3 		– Sell
-24,518
Closed -$528K – 1271
2024
Q2 		$528K Hold
24,518
– – ﹤0.01% 838
2024
Q1 		$661K Hold
24,518
– – ﹤0.01% 800
2023
Q4 		$735K Buy
24,518
+10,538
+75% +$233K ﹤0.01% 774
2023
Q3 		$286K Buy
+13,980
New +$254K ﹤0.01% 968
2021
Q4 		– Sell
-8,190
Closed -$245K – 1470
2021
Q3 		$245K Hold
8,190
– – ﹤0.01% 1371
2021
Q2 		$363K Sell
8,190
-500
-6% -$21.7K ﹤0.01% 1313
2021
Q1 		$386K Sell
8,690
-1,665
-16% -$91.4K ﹤0.01% 1334
2020
Q4 		$568K Buy
+10,355
New +$377K ﹤0.01% 1158

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Los Angeles Capital Management's RCKT Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 187,401 shares — an estimated $693K sold.

Los Angeles Capital Management first reported a position in RCKT in Q4 2020 and held it in 11 quarters. The position peaked at $862K in Q3 2025. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Los Angeles Capital Management reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 187,401 Rocket Pharmaceuticals shares in Q1 2026, an estimated $693K.
  • Los Angeles Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2020 and held it in 11 quarters.
  • Los Angeles Capital Management's Rocket Pharmaceuticals position peaked at $862K in Q3 2025.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.